Business Description
Corcept Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US2183521028
Share Class Description:
FRA:HTD: Ordinary SharesTotal Employee Number:
730Description
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 35.09 | |||||
Equity-to-Asset | 0.78 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | -1.56 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 33.31 | |||||
Beneish M-Score | -3.3 | |||||
WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 22.3 | |||||
3-Year EBITDA Growth Rate | -27 | |||||
3-Year EPS without NRI Growth Rate | -2 | |||||
3-Year FCF Growth Rate | 4.6 | |||||
3-Year Book Growth Rate | 9.5 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 100.28 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 32.83 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 83.92 | |||||
9-Day RSI | 81.29 | |||||
14-Day RSI | 80.94 | |||||
3-1 Month Momentum % | 55.27 | |||||
6-1 Month Momentum % | -25.35 | |||||
12-1 Month Momentum % | -17.31 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.86 | |||||
Quick Ratio | 2.77 | |||||
Cash Ratio | 2.27 | |||||
Days Inventory | 351.25 | |||||
Days Sales Outstanding | 27.99 | |||||
Days Payable | 866.15 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 0.6 | |||||
Shareholder Yield % | -0.01 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 98.25 | |||||
Operating Margin % | -1.07 | |||||
Net Margin % | 6.16 | |||||
EBITDA Margin % | -0.81 | |||||
FCF Margin % | 15.57 | |||||
OCF Margin % | 15.61 | |||||
ROE % | 7.31 | |||||
ROA % | 5.74 | |||||
ROIC % | -1.86 | |||||
3-Year ROIIC % | -16.75 | |||||
ROC (Joel Greenblatt) % | -106.17 | |||||
ROCE % | -1.23 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 242.14 | |||||
Forward PE Ratio | 144.27 | |||||
PE Ratio without NRI | 242.14 | |||||
Shiller PE Ratio | 91.42 | |||||
Price-to-Owner-Earnings | 229.05 | |||||
PS Ratio | 12.81 | |||||
PB Ratio | 14.26 | |||||
Price-to-Tangible-Book | 15.26 | |||||
Price-to-Free-Cash-Flow | 86.48 | |||||
Price-to-Operating-Cash-Flow | 86.22 | |||||
EV-to-EBIT | -1099.68 | |||||
EV-to-EBITDA | -1459.38 | |||||
EV-to-Revenue | 11.75 | |||||
EV-to-Forward-Revenue | 8.64 | |||||
EV-to-FCF | 72.99 | |||||
Price-to-GF-Value | 1.47 | |||||
Price-to-Projected-FCF | 3.61 | |||||
Price-to-Median-PS-Value | 1.72 | |||||
Price-to-Graham-Number | 13.23 | |||||
| Price-to-Net-Current-Asset-Value | 39.08 | |||||
| Price-to-Net-Cash | 60.17 | |||||
Earnings Yield (Greenblatt) % | -0.09 | |||||
FCF Yield % | 1.28 | |||||
Forward Rate of Return (Yacktman) % | -4.39 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Corcept Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 660.735 | ||
| EPS (TTM) (€) | 0.299 | ||
| Beta | -0.3818 | ||
| 3-Year Sharpe Ratio | 0.77 | ||
| 3-Year Sortino Ratio | 1.42 | ||
| Volatility % | 83.59 | ||
| 14-Day RSI | 80.94 | ||
| 14-Day ATR (€) | 1.595132 | ||
| 20-Day SMA (€) | 67.621 | ||
| 12-1 Month Momentum % | -17.31 | ||
| 52-Week Range (€) | 27.49 - 77.24 | ||
| Shares Outstanding (Mil) | 107.35 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Corcept Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Corcept Therapeutics Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-04 17:00 | In 131 days | ||
| Third quarter earnings results for 2026 | 2026-11-04 | In 130 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-31 17:00 | In 35 days | ||
| Second quarter earnings results for 2026 | 2026-07-31 | In 34 days | ||
| General meeting for 2026 | 2026-05-21 07:30 | 50.26 (+1.27%) | ||
| First quarter earnings conference call for 2026 | 2026-04-30 17:00 | 39.49 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-04-30 | 39.49 (+0.00%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-02-24 17:00 | 29.35 (+1.38%) | ||
| Annual report for 2025 | 2026-02-24 | 29.35 (+1.38%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-24 | 29.35 (+1.38%) |
Show
Entries
Corcept Therapeutics Inc Frequently Asked Questions
What is Corcept Therapeutics Inc(FRA:HTD)'s stock price today?
The current price of FRA:HTD is €75.82. The 52 week high of FRA:HTD is €77.24 and 52 week low is €27.49.
When is next earnings date of Corcept Therapeutics Inc(FRA:HTD)?
The next earnings date of Corcept Therapeutics Inc(FRA:HTD) is 2026-07-31 Est..
Does Corcept Therapeutics Inc(FRA:HTD) pay dividends? If so, how much?
Corcept Therapeutics Inc(FRA:HTD) does not pay dividend.
Press Release
Articles on Corcept Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers